ACCOUNTS RECEIVABLE


(In thousands of U.S. dollars)	2013		2012

Accounts receivable – Laser Earn-Out Payment⁽ⁱ⁾	$	4,000	$	—

Accounts receivable – Transition Services⁽ⁱⁱ⁾		—		2,259

Accounts receivable – Other		590		1,701


	$	4,590	$	3,960

(i)

Accounts receivable relates to a milestone payment owing from Valeant related to the receipt of the premarket approval application (“PMA”) supplement for the Qcellus laser from the U.S. Food and Drug Administration (“FDA”) on September 26, 2013. Refer to Note 10 – Contingent Consideration and Note 12 – Discontinued Operations and Assets Held for Sale for more information.

(ii)

Accounts receivable relates to amounts owing from Valeant and Mati for services provided pursuant to respective transition services agreements in connection with the sale of our Visudyne business in 2012 and our PPDS Technology in 2013. Refer to Note 12 Discontinued Operations and Assets Held for Sale for more information. During the year ended December 31, 2013, we recorded a $0.1 million allowance for doubtful accounts provision against these accounts receivable balances (December 31, 2012 – nil).